MBX Biosciences, Inc. Common Stock MBX NASDAQ

NASDAQ Global Select • Healthcare • Biotechnology • US • USD

SharesGrow Score

53/100

3/6 Pass

SharesGrow Intrinsic Value

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

MBX Biosciences, Inc. Common Stock (MBX) has a negative trailing P/E of -13.4, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -7.45%.

Criteria proven by this page:

VALUE (60/100, Pass) — analyst target implies upside (+68.6%).
Trailing Earnings Yield -7.45% — negative yield confirms the company is currently unprofitable. Investors are paying for a turnaround rather than current earnings.
Analyst consensus target $55.33 (+68.6% upside) — significant upside potential according to Wall Street analysts.

Overall SharesGrow Score: 51/100 with 3/7 criteria passed.

SharesGrow 7-Criteria Score

53/100

SG Score

View full scorecard →

✓

VALUE

60/100

Price-to-Earnings & upside

Proven by this page

✓

FUTURE

100/100

Analyst consensus

→ Forecast

✗

PAST

0/100

→ Income

✓

HEALTH

100/100

Debt-to-Equity & liquidity

→ Health

✗

MOAT

40/100

→ Income

✗

GROWTH

15/100

→ Income

—

INCOME

N/A

No coverage

Valuation Snapshot — MBX

Valuation Multiples

P/E (TTM)-13.4

Forward P/EN/A

PEG RatioN/A

Forward PEGN/A

P/B Ratio3.16

P/S Ratio0.00

EV/EBITDA-10.5

Per Share Data

EPS (TTM)$-2.38

Book Value / Share$10.11

Revenue / Share$0.00

FCF / Share$-2.24

Yields & Fair Value

Earnings Yield-7.45%

Dividend Yield0.00%

Analyst Target$55.33 (+68.6%)

Historical Valuation

Year	P/E (TTM)	PEG Ratio	P/B Ratio	Dividend Yield
2022	-28.8	0.00	-17.68	-
2023	-23.1	-0.95	-10.40	-
2024	-9.9	-0.12	2.39	-
2025	-13.2	-0.46	3.12	-

EPS: Actual vs Estimates

P/E Ratio & Earnings Yield

Earnings Per Share (EPS) History

Year	EPS (Diluted)	Revenue	Net Income	Net Margin
2022	$-0.82	$0.00	$-26.14M	-
2023	$-1.02	$0.00	$-32.56M	-
2024	$0.00	$0.00	$-61.92M	-
2025	$-2.38	$0.00	$-86.97M	-

Analyst Estimates

Year	EPS (Avg)	EPS Range	Revenue (Avg)	Revenue Range	Analysts
2026	$-2.85	$-3.10 – $-2.64	$0.00	$0.00 – $0.00	8
2027	$-4.22	$-4.44 – $-3.98	$0.00	$0.00 – $0.00	7
2028	$-4.44	$-6.09 – $-1.94	$26.51M	$26.51M – $26.51M	8
2029	$-3.09	$-3.09 – $-3.09	$131.36M	$131.36M – $131.36M	6
2030	$-1.61	$-1.61 – $-1.61	$256.34M	$256.34M – $256.34M	6